Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Amphista believes that Ian Churcher's scientific leadership will be a tremendous addition to the Amphista team as it progresses its TPD pipeline to the clinic.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Advent Life Sciences
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 07, 2020
Details:
This international financing provides Amphista with a firm foundation to underpin a Series B round to progress its oncology pipeline to the clinic.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
